Incyte Corporation (INCY)
Nasdaq · Healthcare · Biotechnology
$114.13−1.01%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $23.1B
- P/E (trailing)
- 14.5
- Forward P/E
- 13.1
- 52-week range
- $82.82 – $132.60
- 52-week change
- +32.27%
- EPS (trailing)
- $7.85
- Analyst rating
- 2.3 Buy
- Next earnings
- Oct 27, 2026
Fiscal year to Dec 2025
- Revenue
- $5.1B (+21.22%)
- Net income
- $1.3B
- Operating margin
- 29.5%
- Diluted EPS
- $6.41
From the company’s annual report on SEC EDGAR.
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
Headquarters: Wilmington, United States · 2,844 employees · incyte.com